Original title: Lifetime Risk and Years Lived Free of Total Cardiovascular Disease Reference: John T. Wilkins et al. JAMA. 2012; 308(17):1795-1801. This study analyzed more than 120,000 patients in the cohorts of large community studies, such as the Framingham, who did not have cardiovascular disease at the time of inclusion Considering all the age subgroups, only between 1.7%…
A new paradigm in the treatment of in-stent restenosis?
Original title: ISAR DESIRE 3: Drug-eluting balloon is best option for restenosis of limus-eluting stents Reference: Dr Robert Byrne. TCT 2012. Miami, Fl. The first of the ISAR DESIRE trials showed that drug-eluting stents (DES) were the best strategy for treating restenosis of a bare metal stent, the second ISAR DESIRE trial tested the hypothesis of changing or…
Diabetics with multivessel, must keep waiting.
Original title: Strategies for Multivessel Revascularization in Patients with Diabetes. The FREEDOM Trial. Reference: Michael E. Farkouh et al. N Engl J Med 2012. DOI: 10.1056/NEJMoa1211585 This study was designed to determine the best revascularization strategy in diabetic patients with multivessel using current techniques of angioplasty (PCI) and surgery (CABG). Randomized 1:1 diabetic patients with injuries > 70%…
Future second-generation stents, today.
Original title: First Serial Assessment at 6 Months and 2 Years of the Second Generation of Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold A Multi-Imaging Modality Study. Reference: John Ormiston et al. Circ Cardiovasc Interv. 2012;5:620-632. The first bioabsorbable stents eluting everolimus showed a 6-month delayed recoil resulting in late lumen loss of 0.44 mm, (intermediate between a metal stent…
Global Risk Score for stratification of patients with multivessel coronary artery disease: A wider look
Reference: Serruys et al J Am Coll Cardiol Intv 2012;5:606–17 SYNTAX Analysis study demonstrates the utility of a new risk score for patients stratification with left main coronary artery or multivessel disease. Numerous studies have demonstrated the value of SYNTAX score to stratify risk of angioplasty and decision-making (angioplasty versus surgery) in patients with multivessel…
Drug-Eluting Stents: device without polymers overcomes limitations of first generations stents
The NEXT randomized trial showed the superiority of a polymer-free amphilimus-eluting stent compared to paclitaxel-eluting stents with permanent polymers The NEXT clinical trial (International Randomized Comparison Between DES Limus Carbostent and Taxus Drug-Eluting Stents in the Treatment of De Novo Coronary Lesions), is a multicenter randomized trial (n=296) comparing coronary amphilimus eluting stent Cre8 (CID,…
Six Months Sufficient for Dual Antiplatelet Therapy
Reference: Kandzari DE, Barrer CS, Leon MB, et al. Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents. JACC Cardiovasc Interv 2011; 4: 1119-28.2011; 4: 1119-28. Patients treated with zotarolimus-eluting stents (ZES) suffer no excess late ischemic events if they take dual antiplatelet therapy for 6 months instead of 12 months or longer,…
Incomplete Revascularization Linked With Mortality in Multivessel Disease Patients
Reference: Wu C, Dyer AM, Kinas SB, et al. Impact of incomplete revascularization on long-term mortality after coronary stenting. Circ Cardiovasc Interv 2011; 4: 413-21. Complete revascularization was defined as a reduction of stenosis to less than 50% in all diseased (≥ 70% stenosis) lesions in major epicardial coronary vessels at the initial hospitalization or within…
Off-Pump CABG Reduces Postoperative Stroke vs. Standard Surgery
Reference: Afilalo J, RAsti M, Ohayon SM, et al. Off-pump vs on-pump coronary artery bypass surgery: an updated meta-analysis and meta-reggresion of randomized trials. Eur Heart J 2011. Epub ahead of print. Patients who undergo off-pump coronary artery bypass grafting (CABG) surgery experience nearly one-third fewer postoperative strokes than those who receive standard surgery using cardiopulmonary…
Estenosis aórtica: prevalencia, directrices, nuevos tratamientos y datos actuales.
Estudios epidemiológicos han determinado que una de cada ocho personas de 75 años o mayores sufren de estenosis aórtica (EA) moderada o severa.1 Varios sondeos han mostrado que muchos pacientes con EA severa no se derivan a un equipo cardiológico para evaluar una sustitución de la válvula.2 La sustitución de válvula aórtica (SVA) quirúrgica es…